Cure My Disease

Don't miss your cure!

 Log in / Sign up

Generic cariprazine put to the test: will it match the brand?

NCT ID NCT07691190

Completed Disease control Sponsor: Humanis Saglık Anonim Sirketi Source: ClinicalTrials.gov ↗

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This trial compares a generic form of cariprazine (a drug used for schizophrenia) to the brand-name version Reagila®. Healthy adults aged 18 to 55 receive a single dose of either the generic or brand drug under fasting conditions. The main goal is to see if the generic version is absorbed into the body at the same rate and amount as the brand-name drug.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
cariprazine
What this could lead to
If successful, this could confirm that the generic version of cariprazine is equivalent to the brand-name drug, potentially offering a more affordable treatment option for schizophrenia.
What could go wrong
This is an early-phase bioequivalence study in only 32 healthy people, not patients. It does not test effectiveness or long-term safety, and results may not predict real-world outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SCHIZOPHRENIA 1 (DISORDER) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

schizophrenia 1

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SCHIZOPHRENIA 1 (DISORDER)

Contacts and locations

Locations

  • Cliantha Research Limited

    Gujrāt, Vadodara, 390012, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.